SecBot SecBot
PRESS-RELEASE ·Filed Apr 17, 2026

IOVA

Iovance Biotherapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Activist
Actionable Insight • Neutral

No trading implication from this filing; standard equity grants for new hires. Monitor for larger personnel moves or clinical updates as potential catalysts.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.78
T+0 close · Apr 17, 2026 · via day close
Latest settled
+25.40%
T+60 · $4.74
Vs SPY
+18.62%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 20 $3.78entry
  2. T+1 · 7mo ago −2.12%α −1.46% · $3.70
  3. T+5 · 7mo ago −9.26%α −10.17% · $3.43
  4. T+20 · 6mo ago −10.32%α −14.52% · $3.39
  5. T+60 · 4mo ago +25.40%α +18.62% · $4.74
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Iovance Biotherapeutics granted inducement stock options covering 135,470 shares to twelve new non-executive employees, priced at $3.80 per share with three-year vesting. This is a routine hiring incentive and does not reflect a material strategic or financial change.

Key Facts

  • Iovance granted stock options for 135,470 shares to twelve new non-executive employees.
  • Options were granted under the 2021 Inducement Plan, compliant with Nasdaq Rule 5635(c)(4).
  • Exercise price is $3.80, equal to the closing price on the grant date (April 16, 2026).
  • Vesting: one-third on first anniversary, remainder over eight quarterly installments thereafter.
  • No executive-level hires or material financial terms disclosed.

Financial Impact

Minimal near-term financial impact; dilution from 135,470 shares (~0.03% of 440M outstanding shares, based on $1.6B market cap).

dilutionshare_count

Risk Factors

  • Minor dilution over time as options vest.
  • No performance conditions tied to vesting, though standard for inducement grants.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3276514

Track record

21 reports on IOVA

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
  5. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
  6. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
  8. Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
  9. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
  10. Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026